About FibroNox

FibroNox is focused on developing patented first-in-class therapeutics to treat and reduce life-threatening fibrotic diseases. FibroNox has pioneered the development of selective Nox4 inhibitors and Nrf2 activators, has shown robust protection from fibrosis development in preclinical models, and has promoted the reduction of age-associated established fibrosis. FibroNox’s initial focus is treating idiopathic pulmonary fibrosis and fibrosis in Duchenne muscular dystrophy. FibroNox’s therapeutics offer the opportunity to stop and reduce age-associated established fibrosis, representing the holy grail for more effective strategies for fibrotic diseases.